News|Articles|October 31, 2024
Pharmatech Insights – Biosimilar Development: Interacting with the FDA
Author(s)Pharmatech
To help provide patients with greater access to safe, effective biological products, the FDA approves biosimilars on an abbreviated pathway. How should you work with the FDA to navigate this pathway?
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5